Over 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study, published in Science, from researchers at the Perelman School of Medicine at the ...

A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers cellular inflammation and aging and is linked to Alzheimer's disease, ...

A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...

A HUSBAND from Christchurch has put into writing the experience of his wife living with Parkinson’s in his debut book. Laurence Phillips lives in the town with his wife Estelle Phillips, who has had ...

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...